Remove Engineering Remove Pharmacology Remove Safety
article thumbnail

Handling HPAPIs safely – what does it take?

European Pharmaceutical Review

1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. What training is required for employees to handle HPAPIs safely?

Safety 98
article thumbnail

Angion stock falls after agreeing Elicio Therapeutics merger

pharmaphorum

Angion chalked up a series of trial failures for its hepatocyte growth factor (HGF) mimetic ANG-3777 over the last couple of years, and turned its attention to tyrosine kinase receptor inhibitor ANG-3070 in kidney diseases and fibrotic disorders, before abandoning the drug due to safety concerns in the middle of 2022. Darrell Irvine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancing AOCs to transform the delivery of RNA therapeutics

European Pharmaceutical Review

Based on learnings from ASOs and siRNAs they also leverage unique engineering and drug delivery techniques that enable them to target a broader set of cell types, including many that have been previously untreatable with RNA therapeutics. 8 In contrast, AOCs are not limited to RNA degradation or splicing modification alone.

Safety 98
article thumbnail

Uncovering the potential of ADCs to target tumours

European Pharmaceutical Review

The main trend in ADC development] has been an advancement in the engineering changes related to the drug to antibody ration (DAR)” The main change has been an advancement in the engineering changes related to the drug to antibody ration (DAR). What are two of the main trends in ADC development?

article thumbnail

Embracing green innovation in life sciences

European Pharmaceutical Review

At Chiesi, we are conducting the same rigour in terms of safety and bioavailability studies as we would for a new molecule, navigating regulatory and reimbursement discussions, and having to build entirely new manufacturing sites and capabilities. ACS Sustainable Chemistry & Engineering. Pulmonary Pharmacology & Therapeutics.

article thumbnail

Beyond animal testing: the rise of organs-on-chips technology

Clarivate

They became integral to physiological and pharmacological research during the 19th century and started to be systematically used for drug development during the 20th century. Since then, animal-based testing has been the gold standard for establishing a drug’s safety and efficacy. Clinical Pharmacology and Therapeutics, 104(6), pp.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.